Management of hepatitis C virus infection in the Asia-Pacific region: an update-Reference-Cited by-同舟云学术

Management of hepatitis C virus infection in the Asia-Pacific region: an update

Published:2017-01 Issue:1 Volume:2 Page:52-62
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Lim Seng Gee,Aghemo Alessio,Chen Pei-Jer,Dan Yock Young,Gane Edward,Gani Rino,Gish Robert G,Guan Richard,Jia Ji Dong,Lim Kieron,Piratvisuth Teerha,Shah Samir,Shiffman Mitchell L,Tacke Frank,Tan Soek Siam,Tanwandee Tawesak,Win Khin Maung,Yurdaydin Cihan

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference94 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013;Stanaway;Lancet,2016

3. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt;Sievert;Liver Int,2011

4. Review article: HCV genotype 3—the new treatment challenge;Ampuero;Aliment Pharmacol Ther,2014

5. Hepatitis C: an eastern perspective;Dan;Gastroenterol Clin North Am,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico Drug Screening for Hepatitis C Virus Using QSAR-ML and Molecular Docking with Rho-Associated Protein Kinase 1 (ROCK1) Inhibitors;Computation;2024-08-31

2. Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy;PLOS ONE;2024-05-23

3. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy;Current Drug Metabolism;2024-02

4. A Synopsis of Hepatitis C Virus Treatments and Future Perspectives;Current Issues in Molecular Biology;2023-10-11

5. No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy;Global Health & Medicine;2022-08-31